生物大分子基于纳米载体的策略来输送植物衍生生物活性成分用于癌症治疗：一篇近期综述。
Biomacromolecule-based nanocarrier strategies to deliver plant-derived bioactive components for cancer treatment: A recent review.
发表日期：2023 Aug 30
作者：
Bapi Gorain, Varnita Karmakar, Biswatrish Sarkar, Monika Dwivedi, Janelle Tsui Lyn Leong, Jing Hen Toh, Even Seah, Kang Yi Ling, Kah Yee Chen, Hira Choudhury, Manisha Pandey
来源：
Int J Biol Macromol
摘要：
寻求安全的化疗方法吸引了研究人员探索草药药物的抗癌潜力。由于草药药物的益处的不断增多的证据，希望能够提高癌症患者的生存率得到恢复。然而，植物化学成分在吸收差、稳定性差和生物利用度低等方面遭遇了严重的限制。除了与植物化学成分相关的毒性问题之外，质量控制和有限的监管指导也阻碍了草药治疗癌症的普及。目前正在尝试利用纳米载体来克服现有和新草药药物的限制，生物大分子（如壳聚糖、透明质酸等）已被证明在制造纳米载体和癌症靶向方面非常有效。在所讨论的纳米载体中，脂质体和胶束具备将疏水和亲脂草药成分装载并表面修饰以进行靶向输送的特性。主要地，聚乙二醇（PEG）、转铁蛋白和叶酸被用于表面修饰以改善生物利用度、循环时间和目标性。树状聚合物和碳纳米管对植物化学成分具有较高的负载效率；而固脂体纳米颗粒和纳米乳液适合于疏水提取物的载体。本综述强调揭示草药药物的潜在潜力，并讨论基于纳米载体输送植物化学成分在安全癌症治疗方面的增强临床和临床前结果的延伸利益，而不会影响安全性。© 2023 Elsevier B.V. 发布。
The quest for safe chemotherapy has attracted researchers to explore anticancer potential of herbal medicines. Owing to upsurging evidence of herbal drug's beneficial effects, hopes are restored for augmenting survival rates in cancer patients. However, phytoconstituents confronted severe limitations in terms of poor absorption, low-stability, and low bioavailability. Along with toxicity issues associated with phytoconstituents, quality control and limited regulatory guidance also hinder the prevalence of herbal medicines for cancer therapy. Attempts are underway to exploit nanocarriers to circumvent the limitations of existing and new herbal drugs, where biological macromolecules (e.g., chitosan, hyaluronic acid, etc.) are established highly effective in fabricating nanocarriers and cancer targeting. Among the discussed nanocarriers, liposomes and micelles possess properties to cargo hydro- and lipophilic herbal constituents with surface modification for targeted delivery. Majorly, PEG, transferrin and folate are utilized for surface modification to improve bioavailability, circulation time and targetability. The dendrimer and carbon nanotubes responded in high-loading efficiency of phytoconstituent; whereas, SLN and nanoemulsions are suited carriers for lipophilic extracts. This review emphasized unveiling the latent potential of herbal drugs along with discussing on extended benefits of nanocarriers-based delivery of phytoconstituents for safe cancer therapy owing to enhanced clinical and preclinical outcomes without compromising safety.Copyright © 2023. Published by Elsevier B.V.